DekaBank Deutsche Girozentrale’s Aclaris Therapeutics ACRS Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-22,000	Closed	-$184K	–	1247
2023 Q1	$184K	Hold	22,000	–	–	﹤0.01%	1193
2022 Q4	$349K	Hold	22,000	–	–	﹤0.01%	1121
2022 Q3	$320K	Hold	22,000	–	–	﹤0.01%	1132
2022 Q2	$310K	Hold	22,000	–	–	﹤0.01%	1113
2022 Q1	$388K	Buy	22,000 +2,000	+10%	+$27.3K	﹤0.01%	1104
2021 Q4	$288K	Buy	+20,000	New	+$303K	﹤0.01%	1206
2019 Q3	–	Sell	-21,200	Closed	-$45K	–	990
2019 Q2	$45K	Buy	21,200 +8,500	+67%	+$46.3K	﹤0.01%	1123
2019 Q1	$187K	Buy	12,700 +2,100	+20%	+$13.9K	﹤0.01%	1047
2018 Q4	$74K	Sell	10,600 -2,100	-17%	-$21.6K	﹤0.01%	1105
2018 Q3	$187K	Hold	12,700	–	–	﹤0.01%	1070
2018 Q2	$243K	Hold	12,700	–	–	﹤0.01%	1021
2018 Q1	$234K	Buy	+12,700	New	+$269K	﹤0.01%	971

Other funds holding ACRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DekaBank Deutsche Girozentrale's ACRS Position: Q2 2023 in Review

DekaBank Deutsche Girozentrale sold out of Aclaris Therapeutics (ACRS) in Q2 2023, closing a stake of 22,000 shares — an estimated $184K sold.

DekaBank Deutsche Girozentrale first reported a position in ACRS in Q1 2018 and held it in 12 quarters. The position peaked at $388K in Q1 2022. 133 funds tracked by Wall St. Rank hold ACRS as of Q2 2023.

DekaBank Deutsche Girozentrale reported no remaining Aclaris Therapeutics position as of Q2 2023 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 22,000 Aclaris Therapeutics shares in Q2 2023, an estimated $184K.
DekaBank Deutsche Girozentrale first reported a position in Aclaris Therapeutics in Q1 2018 and held it in 12 quarters.
DekaBank Deutsche Girozentrale's Aclaris Therapeutics position peaked at $388K in Q1 2022.
133 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2023.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2023, filed 25 Jul 2023.